Adicet Bio to Present at Upcoming Investor Conferences

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company, announced participation in two investor conferences in May and June 2022.

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

05/18/2022 - 04:00 PM EDT

MENLO PARK, Calif. & BOSTON--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in two upcoming investor conferences in May and June.

Details of the events are as follows:

H.C. Wainwright Global Investment Conference, May 23-26, 2022

An on-demand presentation will be available beginning Tuesday, May 24^th, 2022, at 7:00 A.M. ET.

Jefferies Healthcare Conference, June 8-10, 2022

Chen Schor, President & CEO, will present on Friday, June 10, 2022 at 8:30 A.M. ET.

The live audio webcast of the presentations can be accessed on the Investors section of Adicet Bio’s website at https://investor.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with CAR and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220518005854/en/

Adicet Bio., Inc.
Investor and Media Contacts

Anne Bowdidge
abowdidge@adicetbio.com

Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com

Source: Adicet Bio, Inc.

Keep reading

More on ACET

All ACET news

Trending in the feed

AIOK

AI OKTO Corp. Declares Special Dividend of $3.50 Per Share Open the live feed